RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent)
Launched by FUNDACIÓN MÉDICA PARA LA INVESTIGACIÓN Y DESARROLLO EN EL AREA CARDIOVASCULAR · Nov 12, 2010
Trial Information
Current as of June 24, 2025
Unknown status
Keywords
ClinConnect Summary
Treatment of patients with bare metal stent restenosis remains a major clinical and technical challenge. Currently, drug-eluting stents are widely used in the management of these patients. Recently, the value of the paclitaxel-eluting balloon in this clinical setting has been suggested. However, there is only scarce observational data on the value of this new balloon in patients with bare metal stent restenosis.
This prospective, multicenter, randomized clinical trial will compare two different interventional strategies (namely, paclitaxel-eluting balloon vs everolimus-eluting stent) in th...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- PATIENT:
- • Age between 20 and 85 years
- • Signed informed consent
- • Acceptance of late angiographic control (6-9 months)
- • Angina and / or objective evidence of ischemia
- LESION:
- • In-Stent restenosis (\> 50% visual) any bare metal stent
- • Knowledge of prior stent location
- Exclusion Criteria:
- PATIENT:
- • Inclusion in another clinical research protocol
- • Women of childbearing age
- • Severe associated systemic disease (including renal or liver failure)
- • Severe depression of left ventricular ejection fraction (LVEF \<25%)
- • Disease that affects life expectancy
- • Recent myocardial infarction ( \<7 days)
- • Time of implantation of the previous BMS \<1 month
- • Severe difficulties expected for late angiographic study
- LESION:
- • Angiographic failure during implementation of initial stent(residual stenosis\> 50%)
- • Image of large thrombus in-stent (\> vessel diameter)
- • Tortuosity or Ca + + with very severe difficulties during prior stent deployment
- • Vessel diameter \<2 mm (visual estimate)
- • Restenosis only "outside" the stent (The edge of the stent is not affected)
- • Completely occlusive restenosis (100%, TIMI 0)
- • Very diffuse restenosis (\> 30 mm length)
About Fundación Médica Para La Investigación Y Desarrollo En El Area Cardiovascular
The Fundación Médica para la Investigación y Desarrollo en el Área Cardiovascular is a leading clinical trial sponsor dedicated to advancing cardiovascular health through innovative research and development. Committed to enhancing patient outcomes, the foundation focuses on conducting rigorous clinical studies that explore novel therapies and interventions in the cardiovascular field. With a multidisciplinary team of experts, the foundation fosters collaboration among healthcare professionals, researchers, and industry partners, ensuring the highest standards of scientific integrity and patient safety. Through its initiatives, the foundation aims to contribute significantly to the understanding and treatment of cardiovascular diseases, ultimately improving the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Valencia, , Spain
Madrid, , Spain
Zaragoza, , Spain
Malaga, , Spain
Barcelona, , Spain
Madrid, , Spain
Alicante, , Spain
Valencia, , Spain
A Coruña, , Spain
Santander, Cantabria, Spain
Granada, , Spain
Madrid, , Spain
Barcelona, , Spain
Barcelona, , Spain
Barcelona, , Spain
Oviedo, Asturias, Spain
Zaragoza, , Spain
L'hospitalet De Llobregat, Barcelona, Spain
Majadahonda, Madrid, Spain
Almeria, , Spain
Palma De Mallorca, Illes Balears, Spain
Pamplona, Navarra, Spain
Vigo, Pontevedra, Spain
Badajoz, , Spain
Malaga, , Spain
Toledo, , Spain
Patients applied
Trial Officials
Fernando Alfonso, MD, PhD
Study Director
Hospital San Carlos, Madrid
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials